Hypoxia-inducible factor 1 is believed to play a prominent role in the survival and developing progress of cancers. As a result, inhibiting α subunit of hypoxia-inducible factor 1 represents an attractive strategy against tumor. Although hypoxia-inducible factor 1α is a hypoxia-regulated subunit, increasing evidence indicates that hypoxia-inducible factor 1α could stable expression under normoxic conditions, regulated by non-hypoxia-mediated mechanisms. However, there are few strategies to target hypoxia-inducible factor 1α under normoxic conditions. Here, we report that ginsenoside 20(S)-Rg3, one of the main active ingredients in red ginseng, restrains hypoxia-inducible factor 1α expression under normal oxygen levels in human ovarian cancer cell lines, SKOV3 and 3AO, which leads to potently inhibits migration of ovarian cancer in vitro and in vivo. 20(S)-Rg3 could decrease the expression of hypoxia-inducible factor 1α by upregulation of prolyl hydroxylase domain protein 1 to promoting hypoxia-inducible factor 1α ubiquitin-proteasome degradation under normal oxygen levels. Furthermore, 20(S)-Rg3 could attenuate the expression of nuclear factor-κ B, which may be another possible mechanism for 20(S)-Rg3 to block ovarian cancer migration. Taken together, our study suggests that 20(S)-Rg3 is a strong inhibitor of hypoxia-inducible factor 1α, which may provide a novel agent for future treatments for ovarian cancer.
Introduction
Although great advances have been made in therapeutic management, ovarian cancer remains the most lethal gynecologic malignancy. Numerous patients with ovarian cancer already harbor tumor invasion and metastasis upon initial diagnosis, which leads to poor prognosis. It has been proved that invasion and metastasis are the major causes for high mortality of ovarian cancer. Therefore, devising novel therapeutic strategies against the invasion and metastasis of ovarian cancer is very important for improving patient outcomes in the clinical treatment.
Hypoxia-inducible factor 1 (HIF-1) is a vitally important transcription factor for intratumoral hypoxia, which can make a significant contribution toward tumor invasion and metastasis. 1 HIF-1 consists of a hypoxia-regulated α subunit and a stable β subunit. Importantly, more and more new medicines targeting HIF-1α have been discovered to block tumor progression. Zhang et al. 2 reported that digoxin suppressed tumor growth by decreasing HIF-1α synthesis. Zagzag et al. 3 demonstrated that geldanamycin could prevent migration of glioma cells through interfering with the induction of HIF-1α. Sluis showed that the gene encoding COMM domain-containing 1 (COMMD1) disrupted HIF-1α/β dimerization and repressed tumor cell invasion. 4 There are two prolyl residues (Pro402 and 564) in human HIF-1α which are called the oxygen degradation domain (ODD). Generally, HIF-1α is rapidly degraded under welloxygenated conditions. The ODD could be post-translationally hydroxylated by prolyl hydroxylase domain (PHD) proteins (PHD1-3). Then, HIF-1α can be recognized by von Hippel-Lindau protein (VHL), an E3 ubiquitin ligase complex, to form a VHL-HIF complex. The formation of the complex leads to degradation by the 26S proteasome. However, evidences are accumulating to suggest that various non-hypoxia-mediated mechanisms might also contribute to HIF-1α stable expression. Tumor necrosis factor alpha (TNF-α) has been proved to regulate chondrocyte HIF-1α protein expression under normoxic conditions. 5 ODD mutations caused HIF-1α protein expression in invasive breast cancer independent of hypoxia. 6 However, there are few strategies to target HIF-1α in tumors under normoxic conditions.
Red ginseng has been widely used in Asian countries as a traditional medicine. Ginsenoside 20(S)-Rg3 is one of the main active ingredients in red ginseng. Because of the different orientations of the C-20 hydroxyl, there are two stereoisomers of Rg3-20(S) and 20(R) forms. It is reported that 20(S)-Rg3 may have more effective antitumor activity than 20(R)-Rg3 due to its orientation of the C-20 hydroxyl, making it an more efficient regulator of ion channels. 7 It has been shown that 20(S)-Rg3 owns a wide spectrum of biological activities including anticancer, anti-inflammatory, and anti-angiogensis. [7] [8] [9] [10] Recently, 20(S)-Rg3 was proved to be capable of promoting senescence and apoptosis in gallbladder cancer, ovarian cancer, and leukemia cells. [10] [11] [12] It has also been demonstrated that 20(S)-Rg3 could suppress cells' migration and invasion in lung cancer and colorectal cancer. 13, 14 Interestingly, our previous results have shown that 20(S)-Rg3 could inhibit the Warburg effect in ovarian cancer cells. 15 All of these above suggest that 20(S)-Rg3, an active and safe nature medicine, has a potential anticancer activity.
Our previous studies have shown that 20(S)-Rg3 could inhibit hypoxia-induced epithelial-mesenchymal transition in ovarian cancer cells by reducing the expression of HIF-1α under hypoxia conditions. 14 Significantly, there are various non-hypoxia-mediated mechanisms that might also lead to HIF-1α stable expression and tumor progression under normoxic conditions. 5 However, there has not been any evidence to show whether 20(S)-Rg3 may regulate HIF-1α expression under normal oxygen levels before. Here, we found the inhibitory effect of the 20(S)-Rg3 on migration of ovarian cancer cells. Mechanism dissection revealed that 20(S)-Rg3 could decrease HIF-1α expression via upregulation of PHD1 expression under normal oxygen levels, besides 20(S)-Rg3 could also inhibit nuclear factor-kappa B (NF-κb) expression. These findings suggest that 20(S)-Rg3 could serve as a novel strategy in treating ovarian cancer.
Materials and methods

Chemicals
Ginsenoside 20(S)-Rg3 is a reference compound (purity ⩾ 99%) purchased from Tasly Pharmaceutical Company (Tianjin, China). 20(S)-Rg3 was dissolved in dimethyl sulfoxide (DMSO) in a 4 mg/mL stock solution and stored at −20°C after filtering by 0.2 mm membrane. The final concentrations of DMSO in the culture medium were less than 0.05%. It was diluted by cell culture media to final concentrations (80 µg/mL for SKOV3, 160 µg/mL for 3AO) for the in vitro study, and diluted by phosphatebuffered saline (PBS) to 5 mg/kg for the in vivo study. The concentrations of the 20(S)-Rg3 were designed according to our previous study. 14 
Cell culture
Human ovarian cancer cell lines, SKOV3 and 3AO, were purchased from the Shanghai Cell Bank of Chinese Academy of Sciences (Shanghai, China) and the Shandong Academy of Medical Sciences (Jinan, China). Cells were grown in RPMI-1640 (Gibco, Grand Island, NY, USA) supplemented with 10% newborn bovine serum (NBS; Sijiqing, Hangzhou, China) and penicillin/streptomycin (100 U/mL of penicillin, 100 µg/mL of streptomycin). These cell lines were cultured at 37°C in a humidified incubator containing 21% O 2 and 5% CO 2 . Cells with a passage number less than 20 were used in all experiments. siRNA transient transfection PHD1 siRNA (siPHD1) and negative control siRNA were designed and synthesized by GenePharma Company (Shanghai, China). The siPHD1 sequence was as follows: 5′-GCAUCACCUGUAUCUAUUATT-3′. This siPHD1 is a very effective siRNA for silencing PHD1 which is chosen according to our previous research. Scrambled siRNA was used as negative control (5′-UUCUCCGAACGUG UCACGUTT-3′). Cells were cultivated in six-well plates (Corning Inc., Corning, NY, USA) at a density of 5 × 10 4 cells/well. siPHD1 or control siRNA was transfected to cells at 40%-50% confluence. Then, 15 µL siRNA transfection reagent (Roche, Indianapolis, IN, USA) mixed with 10 nM siRNA was used to treatment for each well according to the manufacturer's instructions. Total RNA and protein were extracted after incubation with siRNA for 48 and 72 h, respectively. RT-PCR and western blot were used to detect the effect of the siRNA.
Wound-healing assay
SKOV3 and 3AO cells were cultivated in six-well plates (Corning Inc., Corning, NY, USA) at a density of 3 × 10 5 cells/well 24 h before treatment. When the cell density reached more than 90% confluence, the NBScontaining medium was removed, and cells were serum starved for 24 h. Cells were washed with NBS-free media. A line was scratched using the end of a 200 mL pipette tip (time 0 h) and cells were washed with NBS-free media to remove the loose cells. Cells were treated with or without 20(S)-Rg3 for 36 h. Images of migrating cells were sequentially taken after 36 h. More than three images were captured for each wound. The experiments were repeated at least three times.
Transwell migration assay
About 1 × 10 5 cells/well were seeded in the upper transwell chambers (8 mm pore size, 24-well; Millipore Co., Bedford, MA, USA) in serum-free medium, and RPMI-1640 with 20% NBS as chemotactic factor was added to the bottom chambers. After treatment for 24 h at 37°C under 5% CO 2 , the top cells which were not migrated were removed from the upper chamber using a cotton swab. The bottom cells which were migrated through the pores onto the lower side of the filter were fixed with 5% glutaric dialdehyde at 4°C for 30 min, and the cells were washed with PBS (PBS, pH 7.2-7.4: NaCl 137 mmol/L, KCl 2.7 mmol/L, Na 2 HPO 4 10 mmol/L, KH 2 PO 4 2 mmol/L). Then, the cells were stained with Giemsa at room temperature for 30 min. The number of migrant cells in five fields under 200× magnification was counted, and the mean values for five fields were determined. The results were repeated three times.
Western blot
Western blot assay was used to analyze proteins. First, the SKOV3 or 3AO cells were washed with ice-cold PBS for three times and cracked in lysis buffer, radio immunoprecipitation assay (RIPA; Biyuntian, Shanghai, China):protease inhibitor (PI; Roche, Basel, Switzerland): phenylmethanesulfonyl fluoride (PMSF; DingGuo, Shanghai, China) = 50:2:1, on ice for 30 min. Then, the cells were centrifuged at 12,000 r/min for 30 min to collect the supernatant. The Quick Start Bradford Protein Assay Kit (Bio-Rad Inc., Hercules, CA, USA) was used to quantify the level of total cell protein for each sample. The samples were diluted in 5× sodium dodecyl sulfate (SDS) loading buffer (1:50 volume of sample; Biyuntian, Shanghai, China) and boiled for 5 min. An equivalent amount of proteins (no more than 30 µL) from each sample was electrophoresed by 10% sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) for about 40 min and then transferred onto nitrocellulose membranes (0.45 µm, Pall Life Science, Port Washington, NY, USA) using a wet transmembrane device (Amersham Pharmacia Biotech., Piscataway, NJ, USA). After that, the membranes were blocked with 5% non-fat milk (milk was mixed in 1× Tris-buffered saline (TBS) containing 0.1% Tween-20 (TBST): pH 7.6) for about 1 h at room temperature and then incubated overnight at 4°C with the primary antibody-rabbit antibody to E-cadherin (Bioworld Technology, Louis Park, MN, USA) 1:500, rabbit antibody to vimentin (Cell Signaling Technology, Beverly, MA, USA) 1:2000, rabbit antibody to β-actin (Cell Signaling Technology, Beverly, MA, USA) 1:1000, mouse antibody to HIF-1α (Abcam Inc., Cambridge, MA, USA) 1:500, sheep antibody to PHD1 (R&D Systems Inc., Minneapolis, MN, USA) 1:2000, rabbit antibody to VHL (Cell Signaling Technology) 1:1000, mouse antibody to NF-κB (Cell Signaling Technology) 1:10000. All the primary antibody was diluted with 5% non-fat milk. The membranes were washed in 1× TBST (5 min, six times) and then incubated for 1 h at room temperature with the appropriate secondary antibody-horse radish peroxidase (HRP)-conjugated goat anti-mouse/rabbit IgG 1:2000, rabbit anti-sheep IgG 1:1000. All the secondary antibody was diluted with 5% non-fat milk. After washing with 1× TBST (5 min, six times), the membranes were developed using ECL reagent (Santa Cruz Biotechnology, Santa Cruz, CA, USA) and were analyzed by electrochemiluminescence (ECL) detection systems (Bio-Rad Inc.).
RT-PCR
For RT-PCR, the cells were washed with ice-cold PBS for three times and were crushed in 0.5 mL lysis buffer (RNAfast 200; Fastagen Biotech Co., Ltd., Shanghai, China) according to the manufacturer's recommendations. RNA concentration and purity were measured by an ultraviolet (UV) spectrophotometer (Bio-Rad Inc.). Equal concentrations of RNA samples (2.0 mg) were then reverse transcribed to complementary DNA (cDNA) by the RT-PCR system (Applied Biosystems Inc., Foster, CA, USA) using RevertAid First Strand cDNA Synthesis Kit (Thermo Fisher Scientific Inc., Waltham, MA, USA) according to the manufacturer's instructions. The cDNA reaction was performed 5 min at 25°C, followed by 60 min at 42°C and 5 min at 70°C and stored at −20°C. Specific cDNAs were then amplified by RT-PCR system (Bio-Rad Inc.). RT-PCR was performed using the SYBR Green Master Mix (Takara Biotechnology Co. Ltd., Dalian, China) in a 25 µL reaction volume, which contained 12.5 µL of SYBR Green master PCR mix, 0.5 µL of each of forward and reverse primers (20 sµM), 1 µL of diluted cDNA template, and appropriate amounts of sterile distilled water. RT-PCR was performed using the following primers (Shenggong Biotechnological Ltd., Shanghai, China): HIF-1α-F, 5′-ATCCATGTGACCATGAGGAAATG-3′; HIF -1α-R, 5′-TCGGCTAGTTAGGGTACACTTC-3′; PHD1-F, 5′-AGGCTGTCGAAG CATTGGTG-3′; PHD1-R, 5′-GG GATTGTCAACGTGCCTTAC-3′; PHD2-F, 5′-A AGC CCAGTTTGCTGACATT-3′; PHD2-F, 5′-TTACCGACC GAATCTGAAGG-3′; PHD3-F, 5′AGCCCATTTTTGC CAGACTCC-3′; PHD3-R, 5′-GATTTCAGAGCA CGGT CAGTC-3′; VHL-F, 5′-GCAGGCGTCGAAGAGTACG-3′; VHL-R, 5′-CGG ACTGCGATTGCAGAAGA-3′; β-actin-F, 5′-TCCCTGGAGAAGAGCTACGA-3′; β-actin-R, 5′-AG CACTGTGTTGGCGTACAG-3′. β-actin gene was used to normalize the expression levels in subsequent quantitative analyses. The PCR program consisted of an initial melting step of 30 s at 95°C, followed by 40 cycles of 5 s at 95°C, 31 s at 58−60°C. Relative gene expression was analyzed using the 2 −ΔΔCT method. Each sample was performed in triplicate.
Animal study
Female, nude mice (6-to 8-week-old) from Animal Center of Xi'an Jiaotong University Medicine School were fed in specific pathogen free (SPF) barrier facilities and were maintained under 12 h dark/light cycle at 21°C. SKOV3 cells were harvested and mixed with PBS, and then the cells were inoculated (1 × 10 7 SKOV3) into the abdominal cavity of each mice. Mice were randomly divided into two groups (control and 20(S)-Rg3, n = 8/group) and were given tail vein injections of 5 mg/kg 20(S)-Rg3 or the equal volume of PBS every other day for 30 days. The change of rats' body weight and ascites was observed. Following the experiment, the mice were killed and the tumors were excised. Histopathological analysis for tumors was carried out using hematoxylin and eosin (H&E) staining and immunohistochemistry. All the contents of animal experiment we have reported here are in accordance with the ARRIVE (Animal Research: Reporting of In Vivo Experiments) guidelines. The care and use of experimental animals were approved by the ethical committee of the First Affiliated Hospital.
Histological analysis with H&E staining
All the tissue samples from control and treated groups were fixed in 4% formaldehyde overnight at 4°C. Then, they were dehydrated in a graded series of ethanol, embedded in paraffin, sectioned at 2-to 3-µm thickness and stuck onto glass slides. After that, glass slides were stained using H&E for microscopic observation.
Immunohistochemistry
Paraffinized ovarian cancer tissue blocks were sectioned, deparaffinized, and hydrated in descending alcohol dilutions. The primary antibody was an anti-HIF-1α antibody (Abcam Inc., Cambridge, MA, USA). The 3-µm-thick sections were deparaffinized and boiled in 0.01 M citrate buffer (pH 6.0) for 30 min in a microwave oven. The sections were then treated with 0.3% hydrogen peroxide and incubated with 10% normal rabbit serum in PBS for 10 min to block non-specific binding. The sections were then incubated with the primary antibody (1:200) for 2 h at room temperature. Negative control specimens were incubated in PBS. The sections were then washed in TBS. After that the sections were incubated for 30 min at RT with HRP-labeled secondary antibody (MaxVision HRP-Polymer anti-Mouse/Rabbit IHC Kit, 1:200, Maixin Inc., Fuzhou, Fujian, China) and color development with diaminobenzidine (DAB) (Abcam Inc.). Positive and negative immunohistochemistry controls were routinely employed. The results of immunohistochemistry were evaluated by two independent observers unaware of the fate of the tissue site.
Statistical analysis
The Student's t-test was used to analyze the results of transwell migration assay and RT-PCR. All statistical analyses were performed using SPSS software (Chicago, IL, USA). Differences were considered significant (**) at p < 0.01 for all comparisons.
Results
20(S)-Rg3 inhibits migratory ability of ovarian cancer cells
Our previous study showed that 20(S)-Rg3 could inhibit cell growth in a dose-dependent manner, and we also tested the half maximal inhibitory concentration (IC 50 ) for SKOV3 and 3AO cells, respectively. In this study, 80 and 160 mg/mL 20(S)-Rg3 were chosen to treat SKOV3 and 3AO cells, respectively. In our previous studies, migratory ability of ovarian cancer cell lines SKOV3 and 3AO was enhanced greatly under hypoxia conditions. 20(S)-Rg3 could restrain migration of SKOV3 and 3AO cells under hypoxia conditions obviously. 14 In this study, we applied wound-healing assay and transwell assay to test migratory ability of SKOV3 and 3AO cells with the treatment of 20(S)-Rg3 under normoxic conditions. Wound-healing assay showed that in comparison with control cells, the mobility of SKOV3 and 3AO cells was suppressed with the treatment of 20(S)-Rg3 for 24 h (Figure 1(a) ). Similar results were also obtained when we replaced wound-healing assay with transwell assay (Figure 1(b) ). Together, results from Figure 1 
20(S)-Rg3 reduces migration of ovarian cancer cells through suppressing HIF-1α protein expression
Given that stabilization of HIF-1α protein is responsible for progression and metastasis in many types of human cancers, 16 we detected the HIF-1α level of SKOV3 and 3AO cells after 20(S)-Rg3 treatment. We found that there was no change of HIF-1α messenger RNA (mRNA) level in the presence of 20(S)-Rg3 in cells (Figure 2(a) ); however, HIF-1α protein expression decreased significantly in both SKOV3 and 3AO cells treated with 20(S)-Rg3 (Figure 2(b) ). These data indicate that HIF-1α protein level can be post-transcriptionally regulated by 20(S)-Rg3 in both SKOV3 and 3AO cells. 20 (S)-Rg3 could inhibit HIF-1α protein level but have no influence on its mRNA level, which suggested that 20(S)-Rg3 regulated HIF-1α expression via a post-transcriptional mechanism. Ubiquitin-mediated proteasomal degradation is one of the commonest way to the regulate HIF-1α protein level, so we analyzed whether the 26S proteasomespecific PI MG132 could prevent the effect of 20(S)-Rg3 on HIF-1α expression. As expected, we found that when treated with MG132, HIF-1α protein of SKOV3 and 3AO cells was not degraded even in the presence of 20(S)-Rg3 (Figure 3(a) ). This result supports that 20(S)-Rg3 could decrease HIF-1α protein level by promoting ubiquitin/proteasome degradation pathway.
20(S)-Rg3 elevates PHD1 expression to facilitate HIF-1α degradation via the ubiquitin/ proteasome pathway
PHDs and VHL play critical role in HIF-1α ubiquitin/ proteasome-dependent protein degradation. In order to verify whether 20(S)-Rg3 can regulate HIF-1α ubiquitin/ proteasome-dependent protein degradation via PHDs or VHL, we detected the mRNA level of PHDs and VHL in cells after treatment of 20(S)-Rg3 (Figure 3(b) ). We found PHD1 and VHL mRNA were upregulated in both SKOV3 and 3AO cells treated with 20(S)-Rg3, but there was almost no effect of 20(S)-Rg3 on the mRNA level of PHD2 and PHD3. To further confirm the data in mRNA level, we applied western blot to detect the protein level of PHD1 and VHL in SKOV3 cells treated with 20(S)-Rg3, and we found that 20(S)-Rg3 could increase the expression of PHD1, but not the expression of VHL (Figure 4(a) ), which indicated that 20(S)-Rg3 may enhance HIF-1α ubiquitin/ proteasome degradation via increased PHD1 expression.
To further confirm these conclusions that 20(S)-Rg3induced HIF-1α degradation was mediated by PHD1, we applied the interruption approach via knocking down PHD1 with siRNA of PHD1 and found that knocking down PHD1 could partially reverse 20(S)-Rg3-induced HIF-1α degradation (Figure 4(b) ). Together, these results suggest that 20(S)-Rg3 could decrease the expression of HIF-1α dependent on ubiquitin/proteasome degradation pathway via induced expression of PHD1 in ovarian cancer cells.
20(S)-Rg3 suppresses migration of ovarian cancer cells by inhibiting NF-κB
NF-κB plays an important role in cancer cell invasion and migration. 17 Hence, it has been reported that 20(S)-Rg3 could prevent colon cancer cells migration by reducing NF-κB. 18 We also wanted to know whether NF-κB was involved in the process that 20(S)-Rg3 decreased migration of ovarian cancer cells. Interestingly, the results showed that NF-κB expression was impaired notably by 20(S)-Rg3 in SKOV3 cells ( Figure 5 ), which implied that, in ovarian cancer, inhibition of NF-κB was also a possible mechanism for 20(S)-Rg3 to block ovarian cancer migration.
20(S)-Rg3 represses HIF-1α expression in vivo
We had reported that, after continuous monitoring of the ovarian cancer metastasis of intraperitoneal xenograft model, the metastasis of 20(S)-Rg3 group reduced significantly. To demonstrate the HIF-1α results above in vivo animal models, we then xenografted SKOV3 cells into abdominal cavity of 6-to 8-week-old female nude mice. Eight mice were then treated with 20(S)-Rg3, and the other eight mice were treated with vehicle solvent. The subcutaneous tumors were fixated for H&E staining and immunohistochemistry analysis of HIF-1α. We found that results from immunohistochemical (IHC) staining of HIF-1α also matched well with those data in vitro co-culture studies (Figure 6(a) ).
It was interesting that we found that the boundary of hepatic and muscle tissues was damaged by ovarian neoplastic tissue obviously in control group, which was not to seen in 20(S)-Rg3 group (Figure 6(b) and (c)). That may give evidence that 20(S)-Rg3 prevent ovarian cancer metastasis in vivo.
Discussion
Ovarian cancer, with a 5-year survival rate of less than 30%, is the most deadly cancer of gynecological tumor. 19 Strong invasiveness and migration accelerate the progression of ovarian cancer. Consequently, suppression of cancer cells invasion and migration is a key strategy for therapy of ovarian carcinoma. Increasing evidence shows that HIF-1α could promote tumor progression by improving cancer cells' invasion and migration. Therefore, HIF-1α is a significant target for therapy of carcinoma. More and more new medicines which were considered as HIF-1α inhibitors were discovered to block tumor progression. Herein, we present ginsenoside 20(S)-Rg3 which could block ovarian cancer migration by inhibiting HIF-1α expression.
Ginsenoside 20(S)-Rg3 has been proved to have notable anticancer activities, such as accelerating cancer cells senescence and apopotosis, 10, 11 repressing cancer growth, 20 and inhibiting cancer invasion and metastasis. 13, 14 The mechanism of 20(S)-Rg3 suppressing tumor is very complicated. It was reported that 20(S)-Rg3 repressed cancer cell proliferation through mitotic inhibition, DNA replication, and growth factor signaling rebuilding. 21 Some evidences demonstrated that 20(S)-Rg3 mediated some tumor-associated signaling pathways, such as PI3K/ Akt, 10, 12 AMPK, 22 p53, 11 and androgen receptor signaling pathway, 23 which induced cells' apoptosis and senescence. In addition, other results indicated that 20(S)-Rg3 repressing Warburg effect suppressed epithelial-mesenchymal transition to inhibit cancer metastasis 13, 14 and enhanced radiosensitization by reducing vascular endothelial growth factor. 24 However, the possible mechanism is still not clear. In our study, we found 20(S)-Rg3 could block ovarian cancer invasion and migration by suppressing HIF-1α protein Total protein from cells exposed to control, 20(S)-Rg3, or 20(S)-Rg3 plus MG132 (cells pretreated with 20-µM MG132 for 30 min followed by exposure to hypoxia and 20(S)-Rg3 for 24 h), respectively, for 24 h was assessed by western blot and normalized to β-actin. (b) Cells exposed to control and 20(S)-Rg3, respectively, were assessed by real-time PCR for transcription of PHD1, PHD2, PHD3, and VHL. After 20(S)-Rg3 treatment, the transcription of PHD1 and VHL genes was increased in both SKOV3 and 3AO cells. expression with no effect on mRNA level, and we confirmed 20(S)-Rg3 promoted proteasomal degradation of HIF-1α using 26S proteasome-specific PI MG132. Chen et al. 25 also discovered that Rg3 facilitates HIF-1α protein degradation and shortens the half-life of HIF-1α protein significantly in human esophageal carcinoma cell line Eca-109, which was consistent with our result. 20(S)-Rg3 was proved to prevent ovarian cancer growth and intraperitoneal dissemination in nude mice in our previous study (data not shown) and weakened HIF-1α level in vivo. These discovery support 20(S)-Rg3 may become a new HIF-1α inhibitor for tumor therapy.
In our study, we found that the mechanism of 20(S)-Rg3 inhibiting HIF-1α was relevant to proteasomal degradation of HIF-1α. It is known that the level of the HIF-1α protein is modified by PHDs and VHL, which could send HIF-1α to proteasomal degradation under normoxia. Impaired activity of PHDs and VHL, even under normoxia, causes accumulation of HIF-1α and activation of HIF-1α target gene expression. Some therapeutic agents have been proved to inhibit HIF-1α by enhancing its protein degradation. Wogonin, a plant-derived flavone, was shown to heighten HIF-1α prolyl hydroxylation to reduce HIF-1α expression. 26 LW6 was demonstrated to increase VHL to promoting proteasomal degradation of HIF-1α. 27 Apicidin was proved to accelerate degradation of HIF-1α via upregulation of PHD2. 28 Our study revealed that 20(S)-Rg3 elevated PHD1 expression to progress proteasomal degradation of HIF-1α under well-oxygenated conditions.
Increased evidence showed that PHD1 acts as a tumor suppressor, like PHD2 and PHD3. PHD1 could prevent colon carcinoma and breast cancer growth 29, 30 and regulated colorectal cancer chemoresistance. 31 Our data showed that PHD1 played a key role in regulation of HIF-1α. Furthermore, we speculated that PHD1 also mediated ovarian cancer invasion and migration. It is very likely that PHD1 could become a new target for ovarian cancer therapy. Our previous study found that under hypoxia, 20(S)-Rg3 increases not only PHD1 expression but also VHL level to reduce HIF-1α protein. Whereas, we found that under well-oxygenated conditions, 20(S)-Rg3 activated only PHD1 but not VHL to accelerate HIF-1α ubiquitinproteasome degradation. These results suggested that the mechanisms of the effect for 20(S)-Rg3 under normoxia or hypoxia were different. But why the situations under normoxia or hypoxia were different require further study. It is essential to clarify the mechanism for 20(S)-Rg3 working under normoxia conditions. Because HIF-1α shows significant upregulation in ovarian cancer under well-oxygenated conditions, it means that inhibition of HIF-1α under normoxia conditions is very important for ovarian cancer therapy. In addition, our data showed that 20(S)-Rg3 can reduce NF-κB expression, which may be another possible mechanism for 20(S)-Rg3 decreasing HIF-1α. It was reported that 20(S)-Rg3 could inhibit NF-κB in variety of tumors 18, 32 and which is also a possible pathway to suppressing cancer growth and progression.
Collectively, we revealed that natural medicine ginsenoside 20(S)-Rg3 hindered ovarian cancer invasion and migration through decreasing HIF-1α protein level under normoxia. We found the mechanisms involved in upregulation of PHD1 by 20(S)-Rg3 which caused HIF-1α ubiquitinproteasome degradation. Although the specific mechanism is still unclear, our data would suggest that 20(S)-Rg3 could became a new drug for ovarian cancer therapy.
